Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 15 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 15 IN PLASTIC CONTAINER.
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% is a parenteral nutrition solution providing amino acids, dextrose, and electrolytes. The amino acids serve as substrates for protein synthesis; dextrose supplies caloric energy; electrolytes maintain acid-base balance and osmotic equilibrium.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
Intravenous infusion: 1-2 L/day as total parenteral nutrition; typical rate 100-125 mL/hour based on caloric and nitrogen needs.
None Documented
None Documented
Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours.
Not applicable as a single agent; components have varying half-lives: dextrose ~2 h (glucose), amino acids ~1-3 h (plasma clearance), electrolytes proportional to renal function
Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible.
Renal: 100% (primarily as free water and electrolytes; dextrose is metabolized; amino acids are deaminated and urea is excreted renally)
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution